ArticleWorld journal of surgical oncology2025
Prognostic value of neutrophil-to-lymphocyte ratio and CA 19-9 in overall survival of patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Factors in Colorectal Cancer Patients with Synchronous Peritoneal Metastasis Undergoing Macroscopic Complete Resection: A Multicenter Prospective Observational Study.Journal of the anus, rectum and colon · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe neutrophil-to-lymphocyte ratio and other inflammatory factors have been used as prognostic indicators in several cancers. This study aims to evaluate the prognostic value of inflammatory factors and tumor markers in patients with peritoneal metastasis of colorectal cancer (CRC) after undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
methodsWe collected data from 116 patients who underwent CRS and HIPEC for peritoneal carcinomatosis of colorectal origin between August 2015 and December 2018 at Hubei Cancer Hospital. Kaplan-Meier analysis was used to calculate overall survival (OS) and Progression-Free-Survival (PFS). Univariate and multivariate Cox regression analyses were conducted to evaluate the influence of inflammatory factors and tumor markers on OS and PFS.
resultsThe median OS was 52.63 months (95% CI 46.02-59.25), and the median PFS was 27.03 months(95% CI 23.35-30.72). Significant differences in OS and PFS were observed between patients with NLR < 2.33 and those with NLR ≥ 2.33(65.38 vs. 44.20, p = 0.005, 35.49 vs. 21.90, p < 0.001). Patients with CA 19-9 > 36.65 also showed significantly poorer OS and PFS compared to patients with CA 19-9 ≤ 36.65(34.86 vs. 65.68, p < 0.001, 17.80 vs. 34.00, p < 0.001). Multivariate analyses suggested that NLR < 2.33, PCI < 10, and CA 19-9 ≤ 36.65 were independent predictive factors for better OS and PFS.
conclusionsPreoperative NLR and CA 19-9 may serve as prognostic markers in patients with peritoneal metastasis of CRC undergoing CRS and HIPEC. These markers may have potential value as selection tools for determining the suitability for CRS + HIPEC in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.